BioRestorative Therapies, Inc. (NASDAQ: BRTX) Q2 2025 Earnings | 08/13/2025

7 days ago

21:23

Inside Ticker

Earnings Calls

AI Summary

Key Highlights:

Financial Results:
- Q2 2025 revenue: $303,000 (up 240% YoY) due to growth in contract manufacturing for biocosmeceuticals.
- Net loss: $2.7M ($0.30/share) vs. $4M ($0.50/share) in Q2 2024.
- Strong cash position: $7.4M with no debt.
Clinical Programs:
- BRTX-100 (Chronic Lumbar Disc Disease - CLDD):
  - Phase 2 trial progressing well, with over 50% enrollment (target: 99 patients).
  - Promising blinded data from 36 subjects showed:
    - >74% had >50% improvement in function (Oswestry Disability Index).
    - >72% had >50% reduction in pain (Visual Analog Scale).
  - No serious adverse events reported.
  - FDA meeting planned to discuss accelerated regulatory pathway (Type B meeting).
- ThermoStem (Obesity/Metabolic Disorders):
  - Developing brown adipose tissue (BAT)-based therapies as an alternative to GLP-1 drugs (no muscle loss/cardiovascular risks).
  - Active licensing discussions with an undisclosed regenerative medicine company.
Commercial & Operational Updates:
- Biocosmeceuticals business expanding, with improved manufacturing efficiencies.
- Advanced partnership discussions to grow contract manufacturing.
Future Outlook:
- Continued focus on BRTX-100 Phase 2 enrollment and FDA discussions.
- Potential milestones:
  - More clinical data (larger patient pool).
  - FDA regulatory updates post-Type B meeting.
  - Licensing deal for ThermoStem.

Closing Remarks:
Management expressed strong optimism about clinical progress, regulatory pathways, and business growth, positioning the company for a transformative second half of 2025.

About this video

BioRestorative Therapies, Inc. (NASDAQ: BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, reported its financial results for the second quarter ended June 30, 2025, along with a business update. The company achieved approximately $303,000 in revenue, primarily from BioCosmeceutical sales under its exclusive supply agreement with Cartessa Aesthetics, representing a significant 240% increase compared to Q2 2024. Despite revenue growth, the company reported a net loss of $2.7 million, or $0.30 per share, an improvement from a net loss of $4.0 million, or $0.50 per share, in the same period last year. The loss from operations was $3.3 million compared to $2.5 million in Q2 2024. BioRestorative ended the quarter with a strong liquidity position, holding $7.4 million in cash, cash equivalents, and marketable securities, with no outstanding debt. Key strategic updates include the authorization of a $2 million stock repurchase program through June 2026 and the addition of industry veteran Sandy Lipkins to lead strategic alliances and licensing efforts, aiming to expand product sales and partnerships domestically and internationally. The company reported continuing discourse with a commercial-stage regenerative medicine company regarding a potential license for its ThermoStem® metabolic intellectual property. Operationally, BioRestorative continues to advance clinical programs targeting disc and spine diseases and metabolic disorders, including positive trends from its BRTX-100 Phase 2 clinical trial for chronic lumbar disc disease. The company’s "made-in-America" manufacturing approach allows effective cost management despite global supply chain challenges. Risks include the ongoing need to manage operating losses and achieve commercial milestones amid competitive and regulatory environments. BioRestorative remains focused on executing its growth strategy while managing resources efficiently. About Inside Ticker: Inside Ticker delivers timely, in-depth financial news and earnings analysis to empower investors with actionable insights on global companies across sectors. For comprehensive video analysis and real-time updates, visit https://www.insideticker.com/. Hashtags: #BioRestorativeTherapies #BRTX #Q22025 #Earnings #FinancialResults #RevenueGrowth #NetLoss #EPS #StemCells #RegenerativeMedicine #ClinicalTrials #BRTX100 #ThermoStem #MetabolicDisorders #DiscDisease #SpineCare #StockRepurchase #StrategicAlliances #Licensing #BioCosmeceuticals #CartessaAesthetics #R&D #MadeInAmerica #SupplyChain #CashPosition #NoDebt #FinancialHealth #GrowthStrategy #Biotech #HealthcareInnovation #NASDAQ #InvestorRelations #QuarterlyResults #EarningsReport #RegenerativeTherapies #MedicalInnovation #BusinessUpdate

Important Note: The stock market is inherently unpredictable, and forecasts are subject to change based on various factors, including economic conditions and company performance. Always consult multiple sources and consider professional advice before making investment decisions.

AI-Powered Financial Analysis This analysis uses real-time market data. While we strive for accuracy, always verify important financial information and consult with qualified financial professionals before making investment decisions. Past performance does not guarantee future results.